Diana Lake

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

Andrew D. Seidman, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2008 · 604 citations · Full text

Medicine, Oncology, Pharmacology +17

First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer

Gary A. Ulaner, Serge K. Lyashchenko, Christopher C. Riedl et al. · Journal of Nuclear Medicine · 2017 · 182 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Ethan Basch, Amylou C. Dueck, Lauren J. Rogak et al. · JAMA Oncology · 2017 · 133 citations · Full text

Nursing, Oncology, Cancer Symptom Management +15

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Maura N. Dickler, William T. Barry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2016 · 129 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

Maura N. Dickler, Hope S. Rugo, Carey A. Eberle et al. · Clinical Cancer Research · 2008 · 122 citations · Full text

Medicine, Oncology, Pharmacology +17